» Articles » PMID: 24672774

A New Spontaneously Transformed Syngeneic Model of High-grade Serous Ovarian Cancer with a Tumor-initiating Cell Population

Overview
Journal Front Oncol
Specialty Oncology
Date 2014 Mar 28
PMID 24672774
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Improving screening and treatment options for patients with epithelial ovarian cancer has been a major challenge in cancer research. Development of novel diagnostic and therapeutic approaches, particularly for the most common subtype, high-grade serous ovarian cancer (HGSC), has been hampered by controversies over the origin of the disease and a lack of spontaneous HGSC models to resolve this controversy. Over long-term culture in our laboratory, an ovarian surface epithelial (OSE) cell line spontaneously transformed OSE (STOSE). The objective of this study was to determine if the STOSE cell line is a good model of HGSC. STOSE cells grow faster than early passage parental M0505 cells with a doubling time of 13 and 48 h, respectively. STOSE cells form colonies in soft agar, an activity for which M0505 cells have negligible capacity. Microarray analysis identified 1755 down-regulated genes and 1203 up-regulated genes in STOSE compared to M0505 cells, many associated with aberrant Wnt/β-catenin and Nf-κB signaling. Upregulation of Ccnd1 and loss of Cdkn2a in STOSE tumors is consistent with changes identified in human ovarian cancers by The Cancer Genome Atlas. Intraperitoneal injection of STOSE cells into severe combined immunodeficient and syngeneic FVB/N mice produced cytokeratin+, WT1+, inhibin-, and PAX8+ tumors, a histotype resembling human HGSC. Based on evidence that a SCA1+ stem cell-like population exists in M0505 cells, we examined a subpopulation of SCA1+ cells that is present in STOSE cells. Compared to SCA1- cells, SCA1+ STOSE cells have increased colony-forming capacity and form palpable tumors 8 days faster after intrabursal injection into FVB/N mice. This study has identified the STOSE cells as the first spontaneous murine model of HGSC and provides evidence for the OSE as a possible origin of HGSC. Furthermore, this model provides a novel opportunity to study how normal stem-like OSE cells may transform into tumor-initiating cells.

Citing Articles

Combined assembloid modeling and 3D whole-organ mapping captures the microanatomy and function of the human fallopian tube.

Crawford A, Forjaz A, Bons J, Bhorkar I, Roy T, Schell D Sci Adv. 2024; 10(39):eadp6285.

PMID: 39331707 PMC: 11430475. DOI: 10.1126/sciadv.adp6285.


PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma.

Spear S, Le Saux O, Mirza H, Iyer N, Tyson K, Grundland Freile F Cancer Res. 2024; 84(22):3772-3787.

PMID: 39186679 PMC: 7616669. DOI: 10.1158/0008-5472.CAN-23-3890.


NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens.

Rodriguez G, Yakubovich E, Murshed H, Maranda V, Galpin K, Cudmore A Front Immunol. 2024; 14:1295208.

PMID: 38235131 PMC: 10791902. DOI: 10.3389/fimmu.2023.1295208.


FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.

Galpin K, Rodriguez G, Maranda V, Cook D, MacDonald E, Murshed H Sci Rep. 2024; 14(1):787.

PMID: 38191799 PMC: 10774293. DOI: 10.1038/s41598-024-51217-1.


Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer.

Cook D, Galpin K, Rodriguez G, Shakfa N, Wilson-Sanchez J, Echaibi M Commun Biol. 2023; 6(1):1152.

PMID: 37957414 PMC: 10643551. DOI: 10.1038/s42003-023-05529-z.


References
1.
Auersperg N . The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae. Int J Gynecol Pathol. 2013; 32(5):444-53. DOI: 10.1097/PGP.0b013e3182800ad5. View

2.
Scurr L, Guminski A, Chiew Y, Balleine R, Sharma R, Lei Y . Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res. 2008; 14(21):6924-32. DOI: 10.1158/1078-0432.CCR-07-5189. View

3.
Foster R, Buckanovich R, Rueda B . Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 2012; 338(1):147-57. DOI: 10.1016/j.canlet.2012.10.023. View

4.
Walker G, Macleod K, Williams A, Cameron D, Smyth J, Langdon S . Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res. 2007; 13(5):1438-44. DOI: 10.1158/1078-0432.CCR-06-2245. View

5.
Yi S, Hao Y, Nan K, Fan T . Cancer stem cells niche: a target for novel cancer therapeutics. Cancer Treat Rev. 2012; 39(3):290-6. DOI: 10.1016/j.ctrv.2012.10.004. View